Xolair

 

The biotechnology company Tanox (founded by Nancy T. Chang and Tse Wen Chang) started working on anti-IgE antibodies.

Mid-1990s: Collaboration between Tanox, Genentech, and Novartis led to the development of omalizumab (originally known as rhuMAb-E25)

                                                                        Omalizumab

                                                                    Theory To Practice

Omalizumab was the first biologic specifically targeting an immunoglobulin and revolutionized the treatment of allergic asthma       

                        

FDA Approval and Use:

2003 (June): The U.S. FDA approved omalizumab under the brand name Xolair, for the treatment of moderate-to-severe persistent allergic asthma in patients aged 12 and older with elevated IgE levels.

2009: Approved in the EU for chronic spontaneous urticaria (CSU) in patients unresponsive to H1 antihistamines.

2014: U.S. FDA expanded its approval to include chronic idiopathic urticaria (CIU).

2016–2020s: Further studied for conditions like nasal polyps, atopic dermatitis, food allergies, and mast cell disorders.

 

                                                                        Current Events 

Snapshot